Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company.
The new company will mainly use Teijin Group’s core healthcare company, Teijin Pharma’s drug discovery research capabilities, facilities, personnel, technologies, and equipment.
Go deeper with GlobalData
Its name, ownership ratio and other details are yet to be decided.
The two companies aim to conclude a final agreement within the fiscal year ending in March next year and then set up a new company shortly.
In addition to supporting drug discovery research, the new company will investigate and acquire candidate compounds for new drugs.
See Also:
This new company is expected to increase drug discovery support services globally using Teijin and Axcelead’s combined strengths in drug-discovery knowledge, technology, and assets.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTeijin and Teijin Pharma are looking to innovate and boost drug discovery research through their alliance for the early launch of drugs for high medical requirements.
This basic agreement is also claimed to accord with the concept of co-creating drug discovery platforms of Axcelead.
Axcelead owns a group of companies that develop a healthcare platform for drug discovery.
Axcelead DDP is claimed to be the first integrated drug discovery solution provider in Japan.
It operates as the core company of the Axcelead group that took over Takeda Pharmaceutical Company’s drug discovery platform business in 2017.
Axcelead DDP is claimed to offer ‘one-stop’ nonclinical drug discovery research services ranging from drug-target discovery to optimisation of drug candidate compounds and approaches for linking to clinical development.
